Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013;15(4):105.
doi: 10.1186/bcr3448.

Pitfalls in accurate estimation of overdiagnosis: implications for screening policy and compliance

Editorial

Pitfalls in accurate estimation of overdiagnosis: implications for screening policy and compliance

Stephen A Feig. Breast Cancer Res. 2013.

Abstract

Stories in the public media that 30 to 50% of screen-detected breast cancers are overdiagnosed dissuade women from being screened because overdiagnosed cancers would never result in death if undetected yet do result in unnecessary treatment. However, such concerns are unwarranted because the frequency of overdiagnosis, when properly calculated, is only 0 to 5%. In the previous issue of Breast Cancer Research, Duffy and Parmar report that accurate estimation of the rate of overdiagnosis recognizes the effect of lead time on detection rates and the consequent requirement for an adequate number of years of follow-up. These indispensable elements were absent from highly publicized studies that overestimated the frequency of overdiagnosis.

PubMed Disclaimer

Comment on

References

    1. Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res. 2013;15:R41. doi: 10.1186/bcr3427. - DOI - PMC - PubMed
    1. Kalager M, Adami H, Bretthauer M, Tamimi R. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;15:491–499. doi: 10.7326/0003-4819-156-7-201204030-00005. - DOI - PubMed
    1. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;15:1778–1786. - PubMed
    1. Puliti D, Duffy SW, de Koning H, Lynge E, Zappa M, Paci E. EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;15(Suppl 1):42–56. - PubMed
    1. Yen A M-F, Duffy SW, Chen TH, Chen LS, Chiu SY, Fann JC, Wu WY, Su CW, Smith RA, Tabár L. Long-term incidence of breast cancer by trial arm in one county of the Swedish Two County Trial of Mammograpy screening. Cancer. 2012;15:5728–5732. doi: 10.1002/cncr.27580. - DOI - PubMed